INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for approximately 80% of liver cancer cases.^1,2 Most patients with HCC are located in the Asia-Pacific area, and approximately 75% to 90% of these cases are linked to chronic infection with viral hepatitis, predominantly hepatitis B or C.^3-5

In recent years, there has been a notable evolution in the treatment of HCC, with developments in external beam radiotherapy (EBRT) contributing substantially to this evolution. Initially perceived as a modality with restricted application because of concerns over radiation-induced liver disease (RILD),⁶ radiotherapy (RT) has now emerged as an integral element in the multimodal management of HCC. This paradigm shift has been propelled by enhancements in EBRT techniques, such as intensity-modulated RT (IMRT) and stereotactic body RT (SBRT), dramatically improving the precision and efficacy of radiation delivery. Moreover, integrating particle RT, including proton and carbon ion therapy, has expanded therapeutic options, leveraging their unique physical and radiobiological properties to improve outcomes.

HCC presents unique oncologic management challenges because of its complexity and heterogeneity.⁷ While surgical resection and liver transplantation are preferred for early-stage HCC, these options are often unfeasible for most patients who present with advanced disease at diagnosis. Additionally, the liver’s complex anatomy and frequent liver function impairment in patients with HCC add to the treatment challenge. In this context, the role of RT has been reevaluated and expanded, offering new effective treatment avenues for various stages of HCC.

This review aims to offer a comprehensive analysis of the evolving role of RT in HCC treatment. Technical advancements in EBRT will be covered, particularly how IMRT and SBRT have improved treatment outcomes, especially in local tumor control. Additionally, the review will explore the integration of RT with other treatment strategies, such as transarterial chemoembolization (TACE) and systemic therapies, including sorafenib and emerging immunotherapies. The specific application of RT in challenging cases like advanced HCC with macrovascular invasion will also be addressed, underscoring ongoing research and future directions in this rapidly developing field. By presenting this review, we aim to highlight the dynamic and crucial role of RT in the multidisciplinary treatment of HCC, emphasizing its importance in enhancing patient outcomes and the necessity for ongoing research and collaboration in this evolving domain.

EFFICACY OF RT IN HCC

Historically, the role of EBRT in treating malignant hepatic tumors has been limited owing to the risk of RILD. However, technological advances, such as IMRT and three-dimensional conformal RT, now allow for the delivery of optimized dose distributions in fractionated RT regimens. These techniques utilize three-dimensional images obtained by computed tomography to facilitate precise delineation of the target and avoidance structures, including normal liver tissue, during RT planning. Consequently, in the modern era, EBRT is indicated across all stages of HCC.⁸ Notably, RT can be used as a single therapy or as an essential component of a combined modality. EBRT can be mainly performed for patients with difficulties undergoing surgical resection, liver transplantation, or other local treatments. The 3-year local control and survival rate of EBRT (including hypofractionated RT, SBRT, and particle RT) ranged from 81-100% and 60-87%, respectively, and the 5-year local control rate and survival rate ranged from 69-97% and 43-78%, respectively (Table 1).^9-35 Furthermore, the most recent meta-analysis results for patients with HCC who underwent IMRT revealed that the combined response rates and 1-year local control rates were 58% and 84%, respectively.³⁶ The median overall survival (OS) was documented at 13 months, while the pooled OS rates for 1 year and 3 years were recorded as 59% and 23%, respectively.³⁷ In the case of SBRT, multiple studies have proven its exceptional local control, particularly in HCC lesions larger than 3 cm.^38-46 Furthermore, proton beam therapy (PBT) and carbon ion RT (CIRT) have been proven through various studies to provide outstanding disease control and acceptable toxicity.^{19,22,25,47-64} Recent research has shifted focus toward the combined therapy of EBRT with other modalities or the potential of EBRT as an alternative to conventional local treatments in specific liver locations or depending on the patient’s condition and liver function.^65-68 Numerous comparative studies are being reported in this area.

COMBINED TRANSARTERIAL CHEMO- OR RADIOEMBOLIZATION WITH RT

In many real-world clinical settings, EBRT is often performed in conjunction with TACE for HCC.⁶⁹ Several studies have reported comparisons between TACE alone and TACE combined with EBRT (Table 2).^70-78 The 1- and 2-year OS rates for TACE combined with EBRT have been reported to range from 50-100% and 23-100%, respectively. In contrast, for TACE alone, the reported 1-year OS rates vary from 31-88.9% and 2-year OS rates from 14-73.6%. Although the survival rate ranges vary across studies, depending on the stage of HCC and the RT modality used, a common finding is that TACE combined with EBRT generally offers a survival advantage over TACE alone. A meta-analysis has shown that combining TACE and EBRT significantly improves the response rate and the 1- and 3-year survival rates compared with TACE alone.⁶⁹ Additionally, several studies have reported the effectiveness of using EBRT as a salvage treatment option after incomplete TACE.^79-81 In a meta-analysis reported by Yang et al.,⁸² patients who received EBRT ranging from 37.3 to 150 Gy following incomplete TACE showed 1- and 2-year OS rates of 72.3% and 50.5%, respectively. The pooled response and local control rates were 72.2% and 86.6%, respectively. These findings suggest that EBRT can be a feasible and effective local management strategy for HCC following incomplete TACE.

Identifying the appropriate time interval for effective combined treatment of TACE and EBRT is crucial. Several studies have addressed this; Yu et al.⁸³ conducted scheduled interval treatment for unresectable HCC, assuming that a 2-week interval between TACE and RT is optimal. This resulted in 70.4% of patients achieving an objective response, with a median OS of 14.7 months. Moreover, grade 3 or higher liver dysfunction, according to the common terminology criteria of adverse events, occurred in only 2.5% of patients, demonstrating the safety and feasibility of a 2-week treatment interval. Additionally, Byun et al.⁸⁴ analyzed treatment outcomes based on various intervals between TACE and RT, finding that groups receiving early RT within 5 weeks exhibited the highest local failure-free rate. As EBRT is increasingly applied for consolidation or salvage purposes following TACE in HCC cases, it becomes imperative to conduct additional research and validation studies to determine its optimal timing.

Radiation can also be effectively delivered to HCC via transarterial radioembolization (TARE), in addition to EBRT. TARE has been demonstrated to offer superior objective response rates, exceptional local tumor control, and a favorable toxicity profile.^85-89 This technique involves administering 90Y microspheres into the hepatic artery branches that supply the tumor. Despite the proven therapeutic success of TARE in HCC treatment, the application of EBRT following TARE is met with concerns regarding the risk of RILD. Furthermore, there is a scarcity of research on using EBRT after TARE. Hardy-Abeloos et al.⁹⁰ compared the outcomes of SBRT following TARE and SBRT post-TACE. SBRT post-TARE did not demonstrate significant differences in local control and OS compared with post-TACE, although the objective response rate was worse post-TARE. Additionally, grade 3 or higher toxicity and liver decompensation did not show significant differences between the two groups. Conversely, Lam et al.⁹¹ conducted a safety analysis in patients who underwent TARE after previously receiving EBRT. The results indicated that prior exposure of the liver to EBRT increased the risk of hepatotoxicity. However, the cumulative liver dose was not an independent predictor, and a dose-volume histogram analysis revealed that the fraction of liver exposed to >30 Gy (V30) was the strongest predictor of hepatotoxicity. These findings provide insight into the combined therapy of EBRT and TARE, yet all studies are retrospective and involve a limited number of patients, necessitating further validation.

COMPARISON OF SBRT AND RADIOFREQUENCY ABLATION

In cases of early-stage HCC where surgery is not feasible, the current guidelines predominantly recommend radiofrequency ablation (RFA) as the treatment option of choice. However, recent studies have brought to light that the local control rates of SBRT are comparably effective to those of RFA.^38-42 Emerging data increasingly substantiate the effectiveness of SBRT in managing early-stage HCC, evidenced by a 2-year local control rate reaching 90%.⁴³ In various prospective clinical trials, SBRT has consistently demonstrated robust local control, achieving rates between 87% and 100% over a period of 1 year to 3 years.^44-46 In the multinational study conducted by Kim et al.,⁴¹ SBRT was shown to have superior local control rates compared with RFA for small-sized tumors (≤3 cm). Significantly, SBRT demonstrated remarkable treatment outcomes for large-sized tumors located in challenging areas, such as the subphrenic regions, where RFA is typically less effective. Additionally, a recent meta-analysis reported that the pooled 1- and 2-year survival rates for HCC studies were 91.8% and 77.7% after RFA and 89.0% and 76.0% after SBRT, respectively.⁴² The pooled grade ≥3 complication rates were 2.9% for RFA and 2.8% for SBRT. The meta-analysis further revealed that SBRT can be more effective than RFA for tumors larger than 2-3 cm or specific sublocations in the liver, such as the subphrenic or perivascular sites. These findings imply that SBRT can be considered a comparable alternative to RFA in treating early-stage HCC, considering factors such as tumor size, location, and the patient’s condition and history.

This emerging evidence suggests a potential re-evaluation of SBRT’s role in the treatment paradigm for early-stage HCC. Additionally, SBRT has been reported in several studies as a successful alternative to TACE and RFA for recurrent tumors. Moreover, for HCC lesions that recurred after TACE, SBRT markedly outperformed RFA in achieving better outcomes. Consequently, the American Society of Radiation Oncology guidelines have officially recognized SBRT as a viable treatment option.⁹²

EBRT IN ADVANCED HCC WITH MACROVASCULAR INVASION

EBRT has also been demonstrated as a viable and safe option for treating advanced HCC with macrovascular invasion. Studies have indicated that the overall tumor response rate following EBRT ranges from 30% to 96%, with patients experiencing a median survival time of 7 to 34.4 months.^28,93-101 This response rate varies depending on the tumor’s location. Specifically, patients with portal vein tumor invasion exhibited response rates between 30% and 83%. In contrast, those with tumor invasion into the inferior vena cava and right atrium had response rates of 43% to 96%. Notably, the median survival period post-EBRT for HCC patients with invasion of the inferior vena cava and right atrium was recorded at 12.1 months and 9.3 months, respectively.⁹⁹ Hou et al.¹⁵ compared treatment outcomes based on the location of the tumor thrombus in patients with HCC and macrovascular invasion, reporting that patients with inferior vena cava tumor thrombi showed significantly better response rates to EBRT than those with portal vein tumor thrombi. Additionally, Wu et al.¹⁰² conducted a meta-analysis on the treatment outcomes in patients with HCC and macrovascular invasion, according to the RT modality. They reported that proton therapy showed significantly better 1-year and 2-year OS compared with conventional RT or SBRT (proton therapy vs. conventional RT, P=0.005 for 1-year OS, P=0.001 for 2-year OS; proton therapy vs. SBRT, P=0.002 for 1-year OS, P=0.004 for 2-year OS).

A retrospective cohort analysis conducted in multiple centers across Korea showed that 66.7% of patients with HCC and portal vein invasion who underwent EBRT also received a combination treatment involving TACE or hepatic arterial infusion chemotherapy (HAIC).¹⁰³ Further supporting this approach, a recent meta-analysis highlighted that this combination therapy (TACE or HAIC with EBRT) notably enhances the objective response and OS in these patients, as opposed to the results achieved through monotherapies like TACE, HAIC,¹⁰⁴ or sorafenib.¹⁰⁵ Additionally, both retrospective series analyses and a recent randomized controlled trial underscored the superior survival rates achieved in patients with HCC and portal vein invasion when treated with the combined regimen of TACE and EBRT, in contrast to those undergoing sorafenib monotherapy.^106-109

PARTICLE THERAPY FOR HCC

With the advancement of RT techniques, there has been a significant increase in reported studies on meaningful particle therapy in HCC (Table 3).^{19,22,25,47-63} PBT is characterized by its exceptional dose concentration, enabling the safe delivery of high doses directly to tumors. This is particularly advantageous in treating large lesions, which are often challenging to manage with SBRT.¹¹⁰ Additionally, PBT offers effective local control of tumors.¹¹¹ PBT is also effective for HCC with portal vein tumor thrombosis or inferior vena cava tumor thrombosis, conditions that are challenging to treat with surgery or RFA.^28,112 Substantial clinical evidence exists for PBT, particularly when comparing outcomes with various treatment modalities.¹¹³ In a multi-institutional prospective study conducted in Japan, PBT for unresectable HCC showed promising results.¹¹⁴ Over a median follow-up period of 39 months, local recurrence was observed in only 7.8% of cases. Furthermore, the median OS and progression-free survival (PFS) were reported as 48.8 months and 14.7 months, respectively. The 3-year OS and PFS rates were 58.8% and 30.2%, respectively. Additionally, in the most recent study by Bush et al.¹¹³ on untreated HCC, a comparison between TACE and PBT showed nearly identical 2-year OS rates at 68% in both groups (P=0.08), with PBT demonstrating significantly better outcomes in terms of median PFS and local control. Tamura et al.⁶² compared treatment outcomes between surgical resection and PBT in HCC cases where the lesion was less than 10 cm and without vessel invasion. Across all patients, the median survival time was superior in the surgery group compared with PBT. However, no significant difference was observed in relapse-free survival between the two groups. Additionally, results from propensity-score matching analysis indicated no significant difference in OS between the two groups. In a recent phase III randomized controlled trial by Kim et al.²³ in Korea, PBT for HCC lesions ≤3 cm showed comparable efficacy to RFA, the standard treatment. This single-center, non-inferiority trial revealed PBT’s local control rate was not inferior, with locoregional PFS rates at 92.8% vs. 83.2% for RFA. No significant differences were noted in PFS, OS, or toxicity rates. PBT has similar efficacy and an excellent safety profile, evidenced by stable Child-Pugh scores, and has been established as a viable, curative option for small HCC.

In HCC treatment, CIRT has recently been recognized as a noteworthy therapeutic approach.⁶⁴ CIRT, a form of particle RT, leverages carbon ion beams for precise targeting and eradication of cancer cells.⁶⁴ The primary advantages of CIRT lie in its distinctive physical and biological characteristics.¹¹⁵ These carbon ions can deposit concentrated energy within a limited tissue volume, inflicting greater damage to cancer cells with superior biological effectiveness than photons or protons. Additionally, the unique dose distribution of carbon ions facilitates administering a high radiation dose directly to the tumor while substantially reducing the impact on adjacent normal organs.⁶⁴ Several prospective phase I and II studies have rigorously examined the efficacy and feasibility of CIRT for HCC. In a landmark 2004 phase I trial by the National Institute of Radiological Sciences in Japan, dose escalation from 49.5 Gy (relative biological effectiveness [RBE]) to 79.5 Gy (RBE) in 15 fractions exhibited no severe adverse effects or deaths, achieving an 81% local control rate at 3 and 5 years.⁵⁴ The institute’s 2017 combined phase I and II trial results identified maximum tolerated doses at 69.6, 58.0, and 52.8 Gy (RBE) for 12, eight, and four fractions, respectively, with 52.8 Gy (RBE) in four fractions recommended for phase II studies.¹⁹ In two prospective trials led by Shibuya et al.,^61,116 where doses of 52.8 Gy and 60 Gy (RBE) were administered in four fractions, the local control rates achieved were 92.3% at the 2-year mark and 76.5% at 4 years. These studies observed only late-grade 3 hepatobiliary toxicity, indicating a favorable safety profile for this treatment regimen. In a recent phase I trial from China, where doses ranged from 55 to 70 Gy (RBE) in 10 fractions, no dose-limiting toxicity was observed. The trial achieved a 5-year OS and local control rates of 67.1% and 94.4%, respectively.⁴⁹ Limited retrospective studies exist comparing CIRT with other treatment modalities for HCC. According to Shiba et al.,¹¹⁷ CIRT was compared with TACE for a single HCC lesion. Analysis of 17 matched pairs revealed significantly better 3-year outcomes for CIRT, with higher OS (88% vs. 58%), local control (80% vs. 26%), and PFS (51% vs. 15%) than TACE. Fujita et al.¹¹⁸ also compared CIRT with RFA as initial treatments for early-stage HCC. In a cohort of 560 patients, those undergoing CIRT showed significantly lower cumulative intrasubsegmental recurrence rates at 2 years (12.6% vs. 31.7%) and 5 years (15.5% vs. 49.6%). Nevertheless, local control, PFS, and OS rates were similar between the groups. Importantly, the CIRT group experienced no grade 3 or higher adverse events, as opposed to a 1.2% rate in the RFA group.

SYSTEMIC THERAPY COMBINED WITH EBRT

With the advancement of EBRT technology, superior local control in various stages of HCC, including the early stage, has been demonstrated. Nevertheless, RT faces certain limitations in managing advanced HCC. Achieving local tumor control through RT does not consistently result in prolonged patient survival, mainly because of its limitations in addressing liver dysfunction and the risk of metastasis or progression in other organs. Consequently, integrating local and systemic treatments for HCC may offer enhanced survival benefits for patients. In advanced HCC, sorafenib is a crucial option for systemic therapy.⁶⁵ This agent gained approval following the results of two significant randomized controlled trials specifically targeting HCC.^119,120 Currently, sorafenib is recognized as the primary systemic treatment for HCC in patients with preserved liver function (classified as Child-Pugh class A), in cases of advanced-stage HCC (Barcelona Clinic Liver Cancer-C), and HCC cases exhibiting progression post-locoregional therapy. Recent studies, however, have shown that combination therapy of atezolizumab and bevacizumab offers superior OS rates compared with sorafenib alone.¹²¹ While new therapeutic options for HCC have emerged, including lenvatinib as a first-line treatment and nivolumab, regorafenib, ramucirumab, and cabozantinib as second-line treatments,¹²² sorafenib retains its significance in treating advanced HCC. This is because other first-line treatments, besides the atezolizumab-bevacizumab combination, have not demonstrated superiority over sorafenib. Moreover, most second-line therapies are considered in scenarios where sorafenib has not yielded the desired outcomes.

Numerous studies have established the survival benefits of combining sorafenib with EBRT. A multicenter study in Korea demonstrated that concurrent administration of sorafenib and EBRT significantly improved OS compared with sorafenib monotherapy.⁶⁵ Additionally, a nationwide cancer-registry-based study in Taiwan reported that patients receiving sorafenib plus RT had significantly better 1-year survival than those treated with sorafenib alone.⁶⁶ Conversely, a propensity score-matching analysis conducted in Korea indicated that sorafenib administered before or concurrently with EBRT did not significantly impact OS. However, administering EBRT after sorafenib was associated with a significant improvement in OS.⁶⁷ Additionally, a Chinese study using a propensity score-matching analysis found that HCC with macrovascular invasion treated with IMRT and TACE combined with sorafenib showed longer PFS but no significant difference in OS compared with a group without sorafenib.⁶⁸

FUTURE DIRECTIONS AND ONGOING RESEARCH

In the most recent phase 3, multicenter randomized controlled trial (NRG/RTOG 1112) for locally advanced HCC, the treatment outcomes of sorafenib monotherapy were compared with those of a combination therapy involving SBRT (27.5-50 Gy in five fractions) followed by sorafenib.¹²³ The results revealed that the combination therapy significantly enhanced OS and PFS. Additionally, there was no significant difference in grade 3 or higher toxicity between the two groups. These findings underscore the safety and considerable survival benefits of adding SBRT to sorafenib, a commonly used systemic therapy agent in advanced HCC, suggesting a more prominent role for SBRT in future clinical applications.

While immunotherapy has emerged as a primary treatment approach for advanced HCC, its effectiveness varies owing to innate or acquired resistance mechanisms. This variation highlights the critical need for research into combined therapies, integrating immunotherapy with other treatment methods to enhance effectiveness in HCC management.¹²⁴ Pursuing such research is vital for advancing patient care and addressing the current limitations of immunotherapy strategies in HCC. RT can modify the tumor microenvironment, influencing immune response and potentially synergizing with immunotherapies. With the proven efficacy of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in malignant tumors, researchers are actively exploring their combination with RT modalities, including SBRT or proton therapy in HCC treatment. A multicenter phase 2 trial in Korea investigated the concurrent use of nivolumab and EBRT in advanced HCC with macrovascular invasion, reporting promising PFS and safety.¹²⁵ Similarly, a study in Hong Kong comparing SBRT with nivolumab to TACE alone in locally advanced HCC found significantly better survival and reduced treatment toxicity with the combined approach.¹²⁶ Furthermore, an ongoing prospective phase 2 study is evaluating the efficacy and safety of atezolizumab/bevacizumab with PBT in HCC with portal vein invasion. While numerous trials have explored various immunotherapies and RT types across HCC stages, there is still a significant need for data on their synergistic use. These ongoing studies are crucial, as the integration of RT and immunotherapy represents a substantial shift in HCC treatment paradigms. This approach opens new avenues for comprehensive strategies, targeting the tumor and leveraging the body’s immune response, potentially improving patient outcomes in HCC management.

CONCLUSION

This review has thoroughly explored the dynamic role of RT, including advanced modalities like IMRT, SBRT, and particle therapy, in managing HCC. The advancements in RT, particularly with the introduction of particle therapy such as PBT and CIRT, mark a significant leap forward in treating HCC. These techniques offer unique advantages, including precision targeting and reduced risk to surrounding healthy tissue, making them especially valuable in treating complex cases like HCC with macrovascular invasion or in challenging anatomical locations.

The integration of RT with other treatments, such as TACE and systemic therapies, including sorafenib and immunotherapies, has shown enhanced outcomes regarding OS and disease control. This multimodal approach is particularly relevant in advanced HCC, where treatment options were previously limited. The synergistic potential of combining RT with emerging treatments like immunotherapy opens new avenues for comprehensive cancer care, offering hope for better patient outcomes and personalized treatment strategies.

Moreover, the developing field of particle therapy in HCC treatment, demonstrated by the promising outcomes of PBT and CIRT, highlights the necessity for continued research and clinical trials. These advanced RT modalities have yielded promising results, showing improved local control, enhanced survival rates, and diminished treatment-related toxicity, particularly in scenarios where traditional treatments are less effective or unviable.

In conclusion, the role of RT in HCC has expanded significantly, moving beyond traditional limitations to become a cornerstone of modern oncologic management. The continuous advancements in RT techniques, including the emerging field of particle therapy, coupled with the integration of RT into multimodal treatment regimens, are crucial in improving the prognosis and quality of life for patients with HCC. As we progress, the focus on personalized medicine, backed by robust clinical research, will be vital to optimizing treatment strategies and outcomes in HCC management.

Article information

Conflict of Interest

The authors have no conflicts of interest to disclose.

Ethics Statement

This review article is fully based on articles which have already been published and did not involve additional patient participants.

Therefore, IRB approval is not necessary.

Funding Statement

None.

Data Availability

Not applicable.

Author Contribution

Writing - original draft: DK, JSK

Writing - review & editing: DK, JSK

References

• 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 2019;5:1749−1768.PubMedPMC
• 2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17−48.ArticlePubMedPDF
• 3. Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: an Asian perspective comparison. Clin Mol Hepatol 2023;29:252−262.ArticlePubMedPMCPDF
• 4. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24:346−353.ArticlePubMed
• 5. Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology 2015;61:1154−1162.ArticlePubMed
• 6. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237−1248.ArticlePubMed
• 7. Coffin P, He A. Hepatocellular carcinoma: past and present challenges and progress in molecular classification and precision oncology. Int J Mol Sci 2023;24:13274. ArticlePubMedPMC
• 8. Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: diverse global viewpoints. World J Gastroenterol 2020;26:393−403.ArticlePubMedPMC
• 9. Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys 2016;95:477−482.ArticlePubMed
• 10. Chen ZH, Zhang XP, Feng S, Feng JK, Chai ZT, Guo WX, et al. Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: a propensity score matching analysis. Hepatobiliary Surg Nutr 2021;10:646−660.ArticlePubMedPMC
• 11. Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. Int J Radiat Oncol Biol Phys 2020;107:116−125.ArticlePubMed
• 12. Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci 2017;108:497−503.ArticlePubMedPMCPDF
• 13. Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology 2019;69:2533−2545.ArticlePubMedPDF
• 14. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460−468.ArticlePubMedPMC
• 15. Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, Mo HF. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. Jpn J Clin Oncol 2016;46:357−362.ArticlePubMedPMC
• 16. Huang CM, Huang MY, Tang JY, Chen SC, Wang LY, Lin ZY, et al. Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma. World J Surg Oncol 2015;13:201. ArticlePubMedPMCPDF
• 17. Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. Cancer 2020;126:363−372.ArticlePubMedPDF
• 18. Jiang T, Zeng ZC, Yang P, Hu Y. Exploration of superior modality: safety and efficacy of hypofractioned image-guided intensity modulated radiation therapy in patients with unresectable but confined intrahepatic hepatocellular carcinoma. Can J Gastroenterol Hepatol 2017;2017:6267981. ArticlePubMedPMCPDF
• 19. Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer 2017;123:3955−3965.ArticlePubMedPDF
• 20. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839−1846.ArticlePubMed
• 21. Kim JW, Kim DY, Han KH, Seong J. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Dig Liver Dis 2019;51:445−451.Article
• 22. Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, et al. Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma. Front Oncol 2020;10:542. ArticlePubMedPMC
• 23. Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2021;74:603−612.ArticlePubMed
• 24. Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, et al. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatol Res 2021;51:461−471.ArticlePubMedPDF
• 25. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011;117:4890−4904.ArticlePubMed
• 26. Li X, Guo W, Guo L, Lau WY, Ge N, Wang K, et al. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? A propensity score matching study. Oncotarget 2018;9:24537−24547.ArticlePubMedPMC
• 27. Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer 2020;134:41−51.ArticlePubMedPMC
• 28. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 2009;185:782−788.ArticlePubMedPDF
• 29. Park S, Jung J, Cho B, Kim SY, Yun SC, Lim YS, et al. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1953−1959.ArticlePubMedPDF
• 30. Parzen JS, Hartsell W, Chang J, Apisarnthanarax S, Molitoris J, Durci M, et al. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group. Radiat Oncol 2020;15:255. ArticlePubMedPMCPDF
• 31. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399−404.ArticlePubMed
• 32. Yeh SA, Chen YS, Perng DS. The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. J Radiat Res 2015;56:325−331.ArticlePubMedPMC
• 33. Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, et al. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506−515.ArticlePubMedPMCPDF
• 34. Yoon HI, Lee IJ, Han KH, Seong J. Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2014;140:1595−1605.ArticlePubMedPDF
• 35. Zhang T, Zhao YT, Wang Z, Li CR, Jin J, Jia AY, et al. Efficacy and safety of intensity-modulated radiotherapy following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e3789.ArticlePubMedPMC
• 36. Jang WI, Jo S, Moon JE, Bae SH, Park HC. The current evidence of intensity-modulated radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis. Cancers (Basel) 2023;15:4914. ArticlePubMedPMC
• 37. Korean Liver Cancer Association (KLCA), National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583−705.ArticlePubMedPMCPDF
• 38. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452−459.ArticlePubMed
• 39. Yang JF, Lo CH, Huang WY. Is stereotactic body radiotherapy better than radiofrequency ablation for the treatment of hepatocellular carcinoma? J Clin Oncol 2016;34:2797. ArticlePubMedPMC
• 40. Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. J Clin Oncol 2018;36:600−608.ArticlePubMed
• 41. Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol 2020;73:121−129.ArticlePubMed
• 42. Rim CH, Lee JS, Kim SY, Seong J. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: a hybrid meta-analysis. JHEP Rep 2022;5:100594. ArticlePubMedPMC
• 43. Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies. Technol Cancer Res Treat 2018;17:1533033818790217. ArticlePubMedPMCPDF
• 44. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631−1639.ArticlePubMed
• 45. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218−225.ArticlePubMedPDF
• 46. Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget 2016;7:40756−40766.ArticlePubMedPMC
• 47. Bhangoo RS, Mullikin TC, Ashman JB, Cheng TW, Golafshar MA, DeWees TA, et al. Intensity modulated proton therapy for hepatocellular carcinoma: initial clinical experience. Adv Radiat Oncol 2021;6:100675. ArticlePubMedPMC
• 48. Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, et al. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 2019;133:54−61.ArticlePubMedPMC
• 49. Hong Z, Zhang W, Cai X, Yu Z, Sun J, Wang W, et al. Carbon ion radiotherapy with pencil beam scanning for hepatocellular carcinoma: longterm outcomes from a phase I trial. Cancer Sci 2023;114:976−983.ArticlePubMedPMCPDF
• 50. Hsieh CE, Venkatesulu BP, Lee CH, Hung SP, Wong PF, Aithala SP, et al. Predictors of radiation-induced liver disease in Eastern and Western patients with hepatocellular carcinoma undergoing proton beam therapy. Int J Radiat Oncol Biol Phys 2019;105:73−86.ArticlePubMed
• 51. Iizumi T, Okumura T, Sekino Y, Takahashi H, Tsai YL, Takizawa D, et al. Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma. J Radiat Res 2021;62:682−687.ArticlePubMedPMCPDF
• 52. Iizumi T, Okumura T, Hasegawa N, Ishige K, Fukuda K, Seo E, et al. Proton beam therapy for hepatocellular carcinoma with bile duct invasion. BMC Gastroenterol 2023;23:267. ArticlePubMedPMCPDF
• 53. Iwata H, Ogino H, Hattori Y, Nakajima K, Nomura K, Hashimoto S, et al. A phase 2 study of image-guided proton therapy for operable or ablation-treatable primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2021;111:117−126.ArticlePubMed
• 54. Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004;59:1468−1476.ArticlePubMed
• 55. Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 2015;47:34−45.ArticlePubMedPMCPDF
• 56. Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, et al. Does riskadapted proton beam therapy have a role as a complementary or alternative therapeutic option for hepatocellular carcinoma? Cancers (Basel) 2019;11:230. ArticlePubMedPMC
• 57. Okazaki S, Shibuya K, Shiba S, Okamoto M, Miyasaka Y, Osu N, et al. Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe carbon ion radiotherapy for hepatocellular carcinoma in caudate lobe. Hepatol Res 2021;51:303−312.PubMed
• 58. Shiba S, Abe T, Shibuya K, Katoh H, Koyama Y, Shimada H, et al. Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. BMC Cancer 2017;17:721. ArticlePubMedPMCPDF
• 59. Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, et al. Clinical impact of hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma. Radiat Oncol 2020;15:195. ArticlePubMedPMCPDF
• 60. Shibata S, Takamatsu S, Yamamoto K, Mizuhata M, Bou S, Sato Y, et al. Proton beam therapy without fiducial markers using four-dimensional CT planning for large hepatocellular carcinomas. Cancers (Basel) 2018;10:71. ArticlePubMedPMC
• 61. Shibuya K, Katoh H, Koyama Y, Shiba S, Okamoto M, Okazaki S, et al. Efficacy and safety of 4 fractions of carbon-ion radiation therapy for hepatocellular carcinoma: a prospective study. Liver Cancer 2021;11:61−74.ArticlePubMedPMCPDF
• 62. Tamura S, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, et al. A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma. Surg Today 2020;50:369−378.ArticlePubMedPDF
• 63. Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, et al. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. Radiother Oncol 2020;146:187−193.ArticlePubMed
• 64. Byun HK, Kim C, Seong J. Carbon ion radiotherapy in the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2023;29:945−957.ArticlePubMedPMCPDF
• 65. Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, et al. Clinical characteristics of long-term survivors after sorafenib treatment for unresectable hepatocellular carcinoma: a Korean national multicenter retrospective cohort study. J Hepatocell Carcinoma 2021;8:613−623.ArticlePubMedPMCPDF
• 66. Chu SS, Kuo YH, Liu WS, Wang SC, Ho CH, Chen YC, et al. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Sci Rep 2021;11:1614. ArticlePubMedPMCPDF
• 67. Chang WI, Kim BH, Kim YJ, Yoon JH, Jung YJ, Chie EK. Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol 2022;37:387−394.ArticlePubMedPDF
• 68. Zhao Y, Zhu X, Wang H, Dong D, Gao S, Zhu X, et al. Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion. Front Oncol 2019;9:1065. ArticlePubMedPMC
• 69. Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol 2015;1:756−765.ArticlePubMed
• 70. Chen WJ, Yuan SF, Zhu LJ, Sun XN, Zheng W. Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. J BUON 2014;19:692−697.PubMed
• 71. Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003;9:1697−1701.ArticlePubMedPMC
• 72. Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:530−536.ArticlePubMedPDF
• 73. Kim KH, Kim MS, Chang JS, Han KH, Kim DY, Seong J. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. Liver Int 2014;34:784−794.ArticlePubMedPDF
• 74. Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2010;78:180−187.ArticlePubMed
• 75. Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189−1196.ArticlePubMed
• 76. Wu DH, Liu L, Chen LH. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2004;10:2184−2189.ArticlePubMedPMC
• 77. Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004;10:307−316.ArticlePubMed
• 78. Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000;47:435−442.ArticlePubMed
• 79. Byun HK, Kim HJ, Im YR, Kim DY, Han KH, Seong J. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. Strahlenther Onkol 2020;196:132−141.ArticlePubMedPDF
• 80. Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, et al. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;90:1051−1060.ArticlePubMed
• 81. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424−5431.PubMed
• 82. Yang DS, Park S, Rim CH, Yoon WS, Shin IS, Lee HA. Salvage external beam radiotherapy after incomplete transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis and systematic review. Medicina (Kaunas) 2021;57:1000. ArticlePubMedPMC
• 83. Yu JI, Park HC, Lim DH, Kim CJ, Oh D, Yoo BC, et al. Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci 2012;27:736−743.ArticlePubMedPMCPDF
• 84. Byun HK, Kim N, Seong J. Optimal timing of radiotherapy after incomplete transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Yonsei Med J 2021;62:409−416.ArticlePubMedPMCPDF
• 85. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52−64.ArticlePubMed
• 86. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011;54:868−878.ArticlePubMed
• 87. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497−507. e2.ArticlePubMedPMC
• 88. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464−473.ArticlePubMed
• 89. Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, et al. Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int 2015;35:620−626.PubMed
• 90. Hardy-Abeloos C, Lazarev S, Ru M, Kim E, Fischman A, Moshier E, et al. Safety and efficacy of liver stereotactic body radiation therapy for hepatocellular carcinoma after segmental transarterial radioembolization. Int J Radiat Oncol Biol Phys 2019;105:968−976.ArticlePubMed
• 91. Lam MGEH, Abdelmaksoud MHK, Chang DT, Eclov NC, Chung MP, Koong AC, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;87:323−329.ArticlePubMed
• 92. Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 2022;12:28−51.ArticlePubMed
• 93. Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, et al. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci 2013;28:213−219.ArticlePubMedPMCPDF
• 94. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864.ArticlePubMedPMC
• 95. Kim DY, Park JW, Kim TH, Kim BH, Moon SH, Kim SS, et al. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol 2017;122:122−129.ArticlePubMed
• 96. Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. Oncology 2018;94:215−222.ArticlePubMedPDF
• 97. Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, et al. Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein. Liver Cancer 2021;10:151−160.ArticlePubMedPMCPDF
• 98. Lou J, Li Y, Liang K, Guo Y, Song C, Chen L, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. BMC Cancer 2019;19:668. ArticlePubMedPMCPDF
• 99. Rim CH, Jeong BK, Kim TH, Kim JH, Kang HC, Seong J. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). Int J Radiat Biol 2020;96:759−766.ArticlePubMed
• 100. Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review. Radiother Oncol 2018;129:123−129.ArticlePubMed
• 101. Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, et al. Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys 2020;107:106−115.ArticlePubMed
• 102. Wu G, Huang G, Huang J, Lu L, Peng S, Li Y, et al. Comparison of external beam radiation therapy modalities for hepatocellular carcinoma with macrovascular invasion: a meta-analysis and systematic review. Front Oncol 2022;12:829708. ArticlePubMedPMC
• 103. Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int 2017;37:90−100.ArticlePDF
• 104. Zhao Q, Zhu K, Yue J, Qi Z, Jiang S, Xu X, et al. Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a metaanalysis. Ther Clin Risk Manag 2016;13:21−31.ArticlePubMedPMCPDF
• 105. Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag 2018;14:1157−1168.ArticlePubMedPMCPDF
• 106. Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, et al. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int 2014;34:795−801.ArticlePubMedPDF
• 107. Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol 2015;26:320−329.e6.ArticlePubMed
• 108. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018;4:661−669.ArticlePubMedPMC
• 109. Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol 2014;14:84. ArticlePubMedPMCPDF
• 110. Igaki H, Mizumoto M, Okumura T, Hasegawa K, Kokudo N, Sakurai H. A systematic review of publications on charged particle therapy for hepatocellular carcinoma. Int J Clin Oncol 2018;23:423−433.ArticlePubMedPDF
• 111. Spychalski P, Kobiela J, Antoszewska M, Błażyńska-Spychalska A, Jereczek-Fossa BA, Høyer M. Patient specific outcomes of charged particle therapy for hepatocellular carcinoma - a systematic review and quantitative analysis. Radiother Oncol 2019;132:127−134.ArticlePubMed
• 112. Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, et al. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol 2020;146:711−720.ArticlePubMedPDF
• 113. Bush DA, Volk M, Smith JC, Reeves ME, Sanghvi S, Slater JD, et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial. Cancer 2023;129:3554−3563.ArticlePubMed
• 114. Mizumoto M, Ogino H, Okumura T, Terashima K, Murakami M, Ogino T, et al. Proton beam therapy for hepatocellular carcinoma: multicenter prospective registry study in Japan. Int J Radiat Oncol Biol Phys 2024;118:725−733.ArticlePubMed
• 115. Pompos A, Durante M, Choy H. Heavy ions in cancer therapy. JAMA Oncol 2016;2:1539−1540.ArticlePubMedPMC
• 116. Shibuya K, Ohno T, Katoh H, Okamoto M, Shiba S, Koyama Y, et al. A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger. Radiother Oncol 2019;132:230−235.ArticlePubMed
• 117. Shiba S, Shibuya K, Katoh H, Kaminuma T, Miyazaki M, Kakizaki S, et al. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. Radiat Oncol 2019;14:137. ArticlePubMedPMCPDF
• 118. Fujita N, Kanogawa N, Makishima H, Ogasawara S, Maruta S, Iino Y, et al. Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma. Hepatol Res 2022;52:1060−1071.ArticlePubMedPDF
• 119. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25−34.ArticlePubMed
• 120. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378−390.ArticlePubMed
• 121. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894−1905.ArticlePubMed
• 122. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317−370.ArticlePubMedPMCPDF
• 123. Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). J Clin Oncol 2023;41 Suppl 4:489.
• 124. Yang Y, Xiong L, Li M, Jiang P, Wang J, Li C. Advances in radiotherapy and immunity in hepatocellular carcinoma. J Transl Med 2023;21:526. ArticlePubMedPMCPDF
• 125. Kim BH, Park HC, Kim TH, Koh YH, Hong JY, Cho Y, et al. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: a phase II study. JHEP Rep 2023;6:100991. ArticlePubMedPMC
• 126. Chiang CL, Chiu KW, Lee FA, Kong FS, Chan AC. Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol 2021;11:798832. ArticlePubMedPMC

Figure & Data

References

Citations

Citations to this article as recorded by